D Planchard

Mapping the antibody–drug‐conjugates landscape in non–small cell lung cancer: Where are we and where are we going?

Claudia Parisi, F Barlesi, D Planchard

Antibody-drug conjugates (ADCs) represent a rapidly advancing therapeutic class in the treatment of non-small cell lung cancer (NSCLC), offering targeted delivery of cytotoxic agents to tumor cells while minimizing off-target toxicity. In recent years, several ADCs have emerged in both early (phase …

fr, it (code pays fourni par la source)

Genomic determinants of resistance to BRAF/MEK inhibitors in BRAF V600E –mutant non–small cell lung cancer.

Eleonora Gariazzo, Alessandro Di Federico, Lodovica Zullo, Alessandro Leonetti et autres

8647 Background: BRAF V600E mutations occur in approximately 2–3% of non–small cell lung cancer (NSCLC). BRAF/MEK inhibition (BRAFi+MEKi) yields high response rates and durable clinical benefit but acquired resistance is inevitable. BRAFi+MEKi therapy may select for resistant tumor clones, induce secondary genomic …

us, fr, it (code pays fourni par la source)

Phase Ib results from the phase Ib/II study of [ 177 Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with extensive-stage small cell lung cancer.

Stephen V. Liu, Pedro Rocha, K Herrmann, Luis G. Paz-Ares et autres

3010 Background: Most pts with newly diagnosed extensive-stage small cell lung cancer (ES-SCLC) relapse after initial response to standard of care (SOC; platinum/etoposide + anti–programmed death-ligand 1 [PD-L1] therapy); novel combination strategies are needed. This Phase Ib/II study (NCT05142696) assessed [ 177 …

us, es, de, fr, il, gb, ch, cn (code pays fourni par la source)

Analysis of spatial atlas of ADC targets in immunotherapy-treated NSCLC to link compartment-specific target expression with tumor immune contexture, clinical outcome, and on-treatment remodeling.

Jean-Philippe Guegan, Zachary Cooper, Krista Kinneer, Jixin Wang et autres

3004 Background: The spatial distribution, co-expression patterns, immune contexture associations, and on-treatment evolution of ADC targets in NSCLC is unknown. Methods: The samples of 100 NSCLC patients treated with PD-1/PD-L1–based immunotherapy (STING NCT04932525) were analyzed using multiplex immunofluorescence with three 7-plex panels …

jp, fr (code pays fourni par la source)

The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinib

Mai Nagasaka, Francesco Facchinetti, Ludovic Bigot, Floriane Brayé et autres

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), effectively targets most single ALK mutations in ALK-positive non-small cell lung cancer (NSCLC), while acquired resistance remains a major clinical challenge. In this study, we identified a novel ALK K1150dup mutation in a patient …

fr, nl, us, jp (code pays fourni par la source)

Lung cancer brain metastases management at the dawn of personalized medicine: are we ready to break the barriers?

A Mavrikios, M Bortolot, C Le Péchoux, J Remon et autres

fr, it, us, gb (code pays fourni par la source)